Abstract
Valeant Pharmaceuticals has agreed to acquire all of the outstanding common stock of the US dermatology company Medicis Pharmaceuticals for US$44 per share in cash. The offer price represents a 39% premium to Medicis’ closing price prior to the announcement of the transaction and values Medicis at approximately US$2.6 B. With the acquisition, Valeant will become the leading player in the US dermatology market.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
